OBJECTIVE: To purify Mannan-binding lectin (MBL) from human serum and detect its binding ability to several kinds of bacteria common in infectious diseases of children. METHODS: MBL was purified from human serum by affinity chromatography on mannan-Sepharose 4B column. Its binding ability to eight species, 97 strains of bacteria was detected by enzyme-linked lectin assay (ELLA). RESULTS: MBL has different binding ability to bacteria and shows strong binding ability to Klebsiella ornithinolytica and Escherichia coli, but shows relatively lower binding ability to Staphylococcus haemolyticus, Enterobacter cloacae and Staphylococcus epidermidis. To different isolates of Klebsiella pneumoniae, Haemophilus influenzae and Staphylococcus aureus, MBL shows quite different binding ability. CONCLUSIONS: MBL has different binding ability to different bacteria, and has relatively stronger binding ability to Gram-negative bacteria. Its binding ability to different isolates of certain kinds of bacteria is quite different.
OBJECTIVE: To purify Mannan-binding lectin (MBL) from human serum and detect its binding ability to several kinds of bacteria common in infectious diseases of children. METHODS:MBL was purified from human serum by affinity chromatography on mannan-Sepharose 4B column. Its binding ability to eight species, 97 strains of bacteria was detected by enzyme-linked lectin assay (ELLA). RESULTS:MBL has different binding ability to bacteria and shows strong binding ability to Klebsiella ornithinolytica and Escherichia coli, but shows relatively lower binding ability to Staphylococcus haemolyticus, Enterobacter cloacae and Staphylococcus epidermidis. To different isolates of Klebsiella pneumoniae, Haemophilus influenzae and Staphylococcus aureus, MBL shows quite different binding ability. CONCLUSIONS:MBL has different binding ability to different bacteria, and has relatively stronger binding ability to Gram-negative bacteria. Its binding ability to different isolates of certain kinds of bacteria is quite different.
Authors: H Valdimarsson; M Stefansson; T Vikingsdottir; G J Arason; C Koch; S Thiel; J C Jensenius Journal: Scand J Immunol Date: 1998-08 Impact factor: 3.487
Authors: Alex Smithson; Ana Muñoz; Belen Suarez; Sara Maria Soto; Rafael Perello; Alex Soriano; Jose Antonio Martinez; Jordi Vila; Juan Pablo Horcajada; Jose Mensa; Francisco Lozano Journal: Clin Vaccine Immunol Date: 2007-01-03
Authors: Ana Moreto; Concepción Fariñas-Alvarez; Maria Puente; Javier Gonzalo Ocejo-Vinyals; Pablo Sánchez-Velasco; Juan Pablo Horcajada; Ana Batlle; Carmen Montes; Francisca Santos; Eulogio Conde; Maria-Carmen Fariñas Journal: BMC Immunol Date: 2014-05-03 Impact factor: 3.615